tenofovir + abacavir + lopinavir/ritonavir — Competitive Intelligence Brief

tenofovir + abacavir + lopinavir/ritonavir (tenofovir + abacavir + lopinavir/ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + PI/boosted). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + PI/boosted) HIV reverse transcriptase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

tenofovir + abacavir + lopinavir/ritonavir (tenofovir + abacavir + lopinavir/ritonavir) — Hospital Clinic of Barcelona. This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tenofovir + abacavir + lopinavir/ritonavir TARGET	tenofovir + abacavir + lopinavir/ritonavir	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI/boosted)	HIV reverse transcriptase, HIV protease
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + PI/boosted) class)

1. Hospital Clinic of Barcelona · 1 drug in this class